Faes Farma licenses Indian rights to bilastine to Merck Serono
Spanish drugmaker Faes Farma has licensed the rights to sell its antihistamine bilastine in India to Merck Serono, the drugs unit of Germany's Merck KGaA. India is Asia's third-largest pharmaceutical market, with a 10% growth rate and an emerging economy of 1.2 billion people. The drug for allergic rhinitis and chronic urticaria was filed for approval with European regulators on February 27, with Germany as the European Union reference member state. Faes has assigned rights to bilastine to privately-held Italian pharmaceutical company Menarini in 51 countries (Marketletter December 24, 2007).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze